Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of furosemide on protein-bound uremic toxins in chronic kidney disease
NL-OMON56204Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of furosemide in chronic kidney disease (CKD), sponsored by University Medical Center Utrecht. Primary endpoint: Protein-bound uremic toxin plasma levels. Started Jun 2024; status: recruiting.
02
Drugs
furosemide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON56204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56204.